Abstract
Background: COVID-19 debilitated communities globally in varying complexities and capacities in recent months.
Objective: The epigenetic changes in the COVID-19 patients were discussed in this article to explore various processes contributing to disease severity and elevation of risk due to infection.
Methods: Percentages of hospitalization, with and without intensive care, in the presence of diseases with increased ACE2 expression, were compared, based on the best available data. Further analysis compared two different age groups, 19-64 and ≥65 years of age.
Result & Conclusion: The COVID-19 disease is observed to be the most severe in the 65 and-higher-age group with pre-existing chronic conditions. This observational study is a nonexperimental empirical investigation of the outcomes of COVID-19 in different patient groups. Results are promising for conducting clinical trials with intervention groups. To ultimately succeed in disease prevention, researchers and clinicians must integrate epigenetic mechanisms to generate valid prescriptions for global well-being.
Keywords: COVID-19, epigenetic, communicable and non-communicable disease, chronic illness, public health, SARS-CoV-2.
[http://dx.doi.org/10.1128/JCM.01967-16] [PMID: 28031438]
[http://dx.doi.org/10.1001/jama.2017.0432] [PMID: 28492888]
[http://dx.doi.org/10.1001/jama.2018.21669] [PMID: 30763433]
[http://dx.doi.org/10.1016/j.jcv.2020.104371] [PMID: 32315817]
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924] [PMID: 32081636]
[http://dx.doi.org/10.20944/preprints202002.0358.v3]
[http://dx.doi.org/10.1002/jmv.25682] [PMID: 31967321]
[http://dx.doi.org/10.1016/S0140-6736(20)30633-4] [PMID: 32197108]
[http://dx.doi.org/10.1038/s41467-019-12348-6] [PMID: 31541153]
[http://dx.doi.org/10.1016/j.jinf.2020.04.021] [PMID: 32335169]
[http://dx.doi.org/10.20944/preprints202003.0295.v1]
[http://dx.doi.org/10.1093/infdis/jiaa332]
[http://dx.doi.org/10.1146/annurev-pathol-011110-130158] [PMID: 20936936]
[http://dx.doi.org/10.1016/j.jcv.2020.104364] [PMID: 32311650]
[http://dx.doi.org/10.3390/biomedicines8070230] [PMID: 32708068]
[http://dx.doi.org/10.1038/nrg2045] [PMID: 17363974]
[http://dx.doi.org/10.5336/pharmsci.2015-44039]
[http://dx.doi.org/10.1371/journal.pone.0040479] [PMID: 22808171]
[http://dx.doi.org/10.1016/j.molcel.2016.04.008] [PMID: 27105110]
[http://dx.doi.org/10.20944/preprints202004.0182.v2]
[http://dx.doi.org/10.1080/1042517021000021608] [PMID: 12487024]
[http://dx.doi.org/10.1016/j.clim.2020.108410] [PMID: 32276140]
[http://dx.doi.org/10.1152/ajpendo.00124.2020] [PMID: 32228322]
[http://dx.doi.org/10.2174/092986711796642562] [PMID: 21756232]
[http://dx.doi.org/10.1016/j.jcv.2020.104359] [PMID: 32302956]
[http://dx.doi.org/10.1001/jama.2020.4812] [PMID: 32208485]
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[http://dx.doi.org/10.20944/preprints202005.0160.v1]
[http://dx.doi.org/10.1097/BOR.0000000000000451] [PMID: 28957963]
[http://dx.doi.org/10.1542/hpeds.2020-0123] [PMID: 32265235]
[http://dx.doi.org/10.3390/pathogens6010008] [PMID: 28212305]
[http://dx.doi.org/10.1146/annurev-publhealth-032013-182513] [PMID: 24641556]